RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy
June 23, 2021 09:00 ET
|
RapidPulse, Inc
MIAMI, June 23, 2021 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15...
Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
April 08, 2021 18:58 ET
|
BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell...
Velano’s PIVO™ Named 2018 MedTech Breakthrough Awards’ Best Overall Medical Device Solution
June 06, 2018 13:06 ET
|
Velano Vascular
SAN FRANCISCO, June 06, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular’s PIVO™ needle-free device for blood draws was named Best Overall Medical Device Solution by the...
Velano Vascular Named 2018’s Gold Edison Award™ Winner
April 17, 2018 08:00 ET
|
Velano Vascular
SAN FRANCISCO, April 17, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular today announced that its PIVO™ needle-free device for blood draws was named the 2018 Gold...
Velano Vascular to Address Healthcare Innovation at Upcoming Spring Conferences
April 10, 2018 08:00 ET
|
Velano Vascular
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular today announced that company leadership will present at a number of premier healthcare...
Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
October 25, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
April 13, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
January 08, 2015 16:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Pricing of Initial Public Offering
October 21, 2014 19:36 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc., a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and...
![Pomona Valley Hospital Medical Center](/news-release/logo/315294/0/315294.jpg?lastModified=12%2F10%2F2016%2008%3A58%3A27&size=2)
Pomona Valley Hospital Medical Center Unveils Life-Saving Tools for Victims of Stroke and Other Vascular Conditions
June 09, 2014 15:08 ET
|
Pomona Valley Hospital Medical Center - MNews
POMONA, Calif., June 9, 2014 (GLOBE NEWSWIRE) -- The chance of surviving a stroke can be increased if the victim gets help right away. Today, Pomona Valley Hospital Medical Center (PVHMC) announced...